Ipsen : Malgré la dépendance croissante à Somatuline, la credit story reste peu risquée. Achat réitéré
Nous refaisons le point à l'occasion des derniers résultats semestriels d'Ipsen. Dans un contexte difficile, le groupe a performé correctement même si la dernière publication témoigne un peu plus du décalage entre la performance impressionnante de Somatuline, le blockbuster du groupe, et celle en demi-teinte des autres produits. Une acquisition d'ampleur est sans doute à l'agenda mais elle ne devrait pas remettre en cause le profil de crédit d’Ipsen à l'horizon de la maturité de ...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.